The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of integrated multi-omics profiling in renal cell carcinoma to identify molecular subtypes and associated clinical outcomes and therapeutic vulnerabilities.
 
Chang Gon Kim
Honoraria - Boryung
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen; Novartis; Ono Pharmaceutical; Pfizer
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Dong-A ST; Hanmi; Merck; MSD Oncology; Novartis; Takeda
Research Funding - Ipsen
 
Harim Koo
No Relationships to Disclose
 
Woo Sun Kwon
No Relationships to Disclose
 
Woo Kyun Bae
No Relationships to Disclose
 
Eu Chang Hwang
No Relationships to Disclose
 
Won Sik Ham
No Relationships to Disclose
 
Nam Hoon Cho
No Relationships to Disclose
 
Jason Sa
No Relationships to Disclose
 
Jong Bae Park
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks